NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
409 trialsNCT05120947 2026-03-17
HART-HN
Medical College of Wisconsin
Phase NA Completed
NCT03386357 2026-03-12
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Erlangen-Nürnberg Medical School
Phase 2 Terminated
NCT03313804 2026-03-11
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
Phase 2 Completed
NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated
NCT03370276 2026-03-10
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT04030455 2026-03-09
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02031250 2026-03-02
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02589938 2026-02-27
ACUPUNCTURE
Wake Forest University Health Sciences
Phase NA Completed
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03656133 2026-02-20
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT04372914 2026-02-20
Prevention of Oral DNA Damage by Black Raspberries
Milton S. Hershey Medical Center
Phase NA Completed
NCT03953976 2026-02-19
INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT03757091 2026-02-18
Flexible Intubation Scope With or Without Video Laryngoscope in Supporting Endotracheal Tube Placement in Patients With Head and Neck Cancer Before Surgery
M.D. Anderson Cancer Center
Phase NA Completed
NCT03993353 2026-02-12
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
Phase 2 Completed
NCT02143726 2026-02-11
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT02749903 2026-02-11
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT01932697 2026-02-10
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Mayo Clinic
Phase 2 Completed
NCT02979977 2026-02-04
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Yale University
Phase 2 Completed
NCT03474497 2026-01-29
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Phase 1/2 Active not recruiting
NCT02919683 2026-01-28
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03468218 2026-01-23
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
Emory University
Phase 2 Active not recruiting
NCT03829722 2026-01-22
Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02819752 2026-01-21
PEACH
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT04326257 2026-01-08
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Phase 2 Completed
NCT05245682 2026-01-08
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Emory University
Phase EARLY_PHASE1 Active not recruiting
NCT03172624 2025-12-18
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04580446 2025-12-15
HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT05152927 2025-12-15
Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
University of California, San Francisco
Phase NA Completed
NCT03347838 2025-12-12
Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
University of Colorado, Denver
Phase 2 Active not recruiting
NCT03109847 2025-12-11
Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers
Thomas Jefferson University
Phase 2 Terminated
NCT04454489 2025-11-19
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
Wake Forest University Health Sciences
Phase 2 Completed
NCT02369458 2025-11-18
Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Washington University School of Medicine
Phase 2 Completed
NCT06129487 2025-11-14
Evaluations of Alcohol Warning Labels
University of Connecticut
Phase NA Completed
NCT03021993 2025-11-12
Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
Medical University of South Carolina
Phase 2 Completed
NCT04463719 2025-11-10
AIM2: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid
University of Florida
Phase NA Completed
NCT05057247 2025-10-31
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02882282 2025-10-23
Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03049618 2025-10-22
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
University of Southern California
Phase 2 Completed
NCT06046482 2025-10-22
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02994069 2025-10-14
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
University of Kentucky
Phase 2 Active not recruiting
NCT03821272 2025-10-08
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients
University of Arkansas
Phase 1/2 Completed
NCT02586207 2025-10-07
Pembrolizumab in Combination With CRT for LA-SCCHN
Sanford Health
Phase 1 Completed
NCT04136912 2025-10-06
3-D Super Resolution Ultrasound Microvascular Imaging
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT03843554 2025-09-26
ARMOR
University of Pennsylvania
Phase NA Terminated
NCT03019003 2025-09-16
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
Massachusetts General Hospital
Phase 1 Completed
NCT02657551 2025-09-11
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04462471 2025-09-08
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03552965 2025-09-02
Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC
University of Arkansas
Phase NA Completed
NCT04105543 2025-09-02
CLR 131 Combined With Radiation for Head and Neck Cancer
University of Wisconsin, Madison
Phase 1 Completed